Strong alliance and win-win development, Huibang Biotech completed the second round of strategic financing

Date：

2021-01-15

Original link  https://mp.weixin.qq.com/s/QWqrh_xddIejiPKJfRzETg

On December 25, 2020, Huibang Biotechnology (Anhui Huibang Bioengineering Co., Ltd., referred to as "Huibang Biology") officially announced the completion of the second round of financing. The signing ceremony was held at the Management Committee of Hefei High-tech Zone. This round of financing was jointly completed by Jiaxing Qihui and Saizhi Capital, with an estimated market value of more than 300 million. It is worth mentioning that nine Huibang strategic partners and provincial agents from all over the country participated in the list of capital parties, which has added a strong guarantee to Huibang's take-off.

 Huibang Biotechnology was formally established in June 2014. Located in Hefei National High-tech Development Zone, it is committed to precision medicine: chronic disease prevention detection reagents, tumor cell detection reagents, maternal and child health diagnostic reagents, cardiovascular disease detection reagents, POCT diagnostic reagents and medical diagnostic mobile Internet +, diagnostic use A high-tech enterprise integrating R&D, production and sales of monoclonal antibody raw materials and medical instruments, has passed the medical device production management regulations and GMP quality system assessments for many times, and has obtained more than 10 medical device registration certificates and more than 30 patents . At present, it is the only IVD manufacturer in Anhui Province with a complete industrial chain development. The three core technology platforms of the industrial chain are: IVD R&D and manufacturing platform, testing equipment R&D and manufacturing platform, and medical monoclonal antibody R&D and preparation platform.

As an original IVD enterprise in the industrial chain, Huibang Biotechnology has always adhered to the high ground of innovation, attaches great importance to independent research and development of core raw materials, takes a differentiated innovation model, acts as a standard setter, truly considers patients and clinical needs, and solves medical difficulties for social hotspots. Pursuing the innovative model of "I have what you have, I have what you don't have", and is determined to break the barriers of foreign technology monopoly and create a national brand - Huibang Bio.

The leading project of Huibang Biotechnology, the non-invasive detection system for diabetic kidney disease, is an exclusive product with independent intellectual property rights in the world. This product is mainly used for early screening of diabetic kidney disease patients, preventing the occurrence and development of diabetic kidney disease (DKD), and filling the technical gap at home and abroad. , has been used in clinical promotion and use, and is well received by experts and front-line medical staff. It will benefit 110 million diabetic patients in China and 450 million diabetic patients worldwide.

 
Huibang Biotechnology has developed a series of core products for the maternal and child health care system, among which the four items of child protection and the dual quantitative abortion and premature delivery dynamic monitoring system are domestic exclusive products, escorting children and pregnant women in China, and promoting the health of fetuses and infants Growth, improve the quality of China's population.
In 2021, Huibang Biotechnology will successively launch a series of quantum dot automatic, dry chemiluminescence, and home self-test products, which will solve the rigid needs of the medical market. Innovation and leadership are the labels of Huibang.
 

Wang Zhongliang, chairman of Huibang Biotechnology, said at the meeting: The journey is strong and the wind is strong, and the heavy responsibility will start again. The company plans to start the listing process on the Science and Technology Innovation Board within the next three years.

Related News

2024-01-22

Serving the big health industry, leapfrogging development of industry, academia and research - Anhui Huibang Biotech bloomed at the Anhui Traditional Chinese Medicine Academic Annual Conference

2023-08-07

Urine and nephropathy and defense -Dialogue column of the Diabetes Branch of the Chinese Medical Association

On August 4, 2023, the Chinese Medical Association Diabetes Branch 2023 Education Management Academic Conference was grandly held at Fengda International Hotel, Hefei City, Anhui Province.

2023-06-29

Good news! Huibang Biotechnology won the second prize of Science and Technology Progress Award of the Ministry of Education!

Recently, the Ministry of Education issued a certificate for the Outstanding Achievement Award (Science and Technology) of Scientific Research in Institutions of Higher Learning. Anhui Huibang Bioengineering Co., Ltd. jointly with the Chinese Academy of Sciences and Capital Medical University declared the project: "Research and Application of Molecular Targets for Diabetes" won the second prize of Science and Technology Progress Award of the Ministry of Education.

2023-06-12

Huibang Biotech actively implements the Hangzhou Declaration and contributes to building a healthy China

On June 11, 2023, the first China Health Promotion Conference was successfully held in Hangzhou. The conference was high-level and large-scale, and many guests from the government, medical and health circles, sports circles, education circles, science and technology circles, mass media, NGO organizations and business circles attended.

2023-06-01

Good news! Huibang Biotechnology won the "Star of Creation" Cup Innovative Product Gold Award

Wisdom medicine is upright and innovative | "Star of Creation" The 8th China Experimental Medicine Conference was grandly opened on May 27 at the Primus Hotel Conference Center in Nanchang! Huibang Bio's innovative product insulin-like growth factor binding protein-1/fetal fiber Connexin (IGFBP-1/fFN) detection kit won the 2022 "Innovation Star" Cup China Excellent Innovative Product Gold Award for In Vitro Diagnostics.